Lisata Therapeutics Shares Financial Results and Key Updates
Lisata Therapeutics Financial Reporting and Updates
LISATA THERAPEUTICS, INC., a prominent clinical-stage pharmaceutical company, is gearing up to share its financial results for the fiscal year ending December 31, 2024. Scheduled for Thursday, February 27, 2025, this announcement will occur after the market closes. The company is known for its innovative therapies aimed at treating advanced solid tumors and other serious diseases.
Participation in the Conference Call
Investors and stakeholders interested in the outcome are encouraged to participate in the conference call that will follow the announcement at 4:30 p.m. Eastern time. To ensure you can join without hassle, it's advisable to register for the call early. Participants will receive an email containing all necessary dial-in information. To ensure a smooth experience, joining the call at least 15 minutes beforehand is recommended.
About Lisata Therapeutics
Lisata Therapeutics stands at the forefront of pharmaceutical innovation, focusing on the discovery, development, and commercialization of advanced therapies for various diseases, particularly advanced solid tumors. Their cyclic peptide product candidate, certepetide, represents a significant advancement in treatment, as it’s designed to enhance drug delivery directly to solid tumors through a novel uptake pathway. This innovative method increases the efficacy of co-administered or tethered anti-cancer drugs.
Strategic Partnerships and Future Goals
The company has already forged remarkable commercial and research partnerships based on its CendR Platform technology. Looking ahead, Lisata Therapeutics anticipates announcing a series of milestones in the upcoming 1.5 years that will enhance their research and operational capabilities. The projected budget is expected to support the company's operations through the second quarter of 2026 as they prepare for key data releases from ongoing and future clinical trials.
Innovative Mechanisms of Action
One of the key highlights of Lisata's product pipeline is the mechanism of action of certepetide. This investigational drug is not only a testament to their commitment to innovation but also provides a pathway for more targeted and effective treatments. The company believes that understanding this mechanism can significantly bolster their position in the market and enhance patient outcomes.
Company Contact Information
For investors seeking more information, Lisata Therapeutics encourages direct contact through:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
For media inquiries:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
Frequently Asked Questions
What are the key focuses of Lisata Therapeutics?
Lisata Therapeutics focuses on developing innovative therapies for advanced solid tumors and other serious diseases, emphasizing precision medicine.
When will Lisata report its financial results?
Lisata Therapeutics plans to report its financial results for the year ending December 31, 2024, on February 27, 2025.
How can investors participate in the conference call?
Investors can register for the conference call through the link provided by Lisata prior to the announcement.
What is certepetide's role in Lisata's product pipeline?
Certepetide is an investigational drug designed to improve the delivery of anti-cancer therapies specifically to solid tumors through a novel uptake mechanism.
Who can I contact for more information on Lisata?
Investors can contact John Menditto via email or phone, while media inquiries can be directed to Elizabeth Coleman.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
